- Home
- KURA vs FFC Comparison
KURA vs FFC Comparison
Compare KURA & FFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KURA | FFC |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 772.8M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | KURA | FFC |
|---|---|---|
| Price | $10.86 | $16.22 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $25.56 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 82.5K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $28.28 | N/A |
| Revenue Next Year | $106.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $6.95 | $14.98 |
| 52 Week High | $12.49 | $17.00 |
Technical Indicators
Market Signals| Indicator | KURA | FFC |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | 52.45 |
| Support Level | $8.63 | $15.95 |
| Resistance Level | $11.40 | $16.34 |
| Average True Range (ATR) | 0.57 | 0.12 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 84.34 | 67.21 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.